A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants

Part of paid clinical trials in Anaheim, California.

Sponsor
AbbVie
Study ID
NCT07466550
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.

Key Dates

First listed
Mar 12, 2026
Start date
Jun 4, 2026
Status verified
Jun 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Risankizumab Dose A
    Participants will receive Dose A of risankizumab via intravenous (IV) infusion.
  • Experimental: Risankizumab Dose B
    Participants will receive Dose B of risankizumab via subcutaneous (SC) injection.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to Approximately 155 Days ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
CenExel ACT- Anaheim Clinical Trials /ID# 281821AnaheimCalifornia92801-
Cpmi /Id# 281783MiamiFlorida33172-

Find similar trials in Anaheim, CA

By research site
CenExel ACT- Anaheim Clinical Trials· Anaheim, CACpmi· Miami, FL

Related Studies